Proactive Investors - Run By Investors For Investors

Enzo Biochem’s $22 million in fiscal 3Q net income includes $29 million stemming from legal settlement

Cash and cash equivalents were $64 million and working capital $71 million
Enzo researches, develops, manufactures, and markets diagnostic and research products

Enzo Biochem Inc (NYSE:ENZ) reported fiscal third-quarter net income of $22.3 million, which included nearly $29 million in cash stemming from an intellectual property settlement.

On a per-share basis, the New York-based company earned $0.47 per share, compared to a net loss of $3 million, or $0.06 per share, in the year-ago quarter.

Enzo said revenue for the quarter, which ended April 30, was $19.7 million – an increase of 2% from the prior-year quarter.

Cash and cash equivalents at the end of the quarter were $64 million and working capital was $71 million, the company said.

Three-pronged strategy

Enzo also announced three-pronged short-term value creation and growth strategy, which includes strategic relationships with leading global life sciences and medical device companies, building a new model for the diagnostic marketplace and returning to operating profitability and growth in the lab segment.

“Enzo is poised to leverage and capitalize on our deep-rooted, proprietary technology, product development and intellectual property portfolio in very real, short-term strategic initiatives designed to unlock the value we know exists across our business,” said CEO Elazar Rabbani.

Enzo researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full ENZ profile View Profile

Enzo Biochem Timeline

Related Articles

June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
Pictured is the company's myLotus test
May 15 2019
Here we take a closer look at testing firm Concepta PLC (LON:CPT)

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use